Tikun Olam-Cannbit Pharmaceuticals Ltd reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was ILS 22.53 million compared to ILS 21.15 million a year ago. Net loss was ILS 67.52 million compared to ILS 9.05 million a year ago.

Basic loss per share from continuing operations was ILS 1.1 compared to ILS 0.2 a year ago. Diluted loss per share from continuing operations was ILS 1.1.